Myristin® cetyl myristoleate (also known as CMO or CM) was discovered by Harry W. Diehl. Diehl took a fatty acid, myristoleic acid, and combined it with a fatty alcohol molecule, cetyl alcohol, creating an ester of that fatty acid called cetyl myristoleate. Diehl's laboratory experiments on CM were published in the Journal of Pharmaceutical Sciences in March, 1994.
Myristin® brand CM/CMO is Diehl's original product, and it is cis-9-cetyl myristoleate, the substance used in Diehl's oft cited research that appeared in the Journal of Pharmaceutical Sciences in March 1994. It is also the substance used in a 32-week, randomized, double blind, placebo-controlled clinical trial by Siemandi, MD, PhD (et al) that is often cited.
Myristin® CM / CMO Suggested Protocol:
One course may be enough for some individuals. Research has indicated better satisfaction when used in conjunction with supportive nutrients for cartilage health (specifically, the ingredients in ReJoin High Potency Joint Support that was designed as a companion product).
Those individuals who do not have success with CM usually just need to take it for a longer period of time; research indicates that the effectiveness of one course varies across individuals.
There are no confirmed reports of adverse side effects with Myristin®, nor have there been any reported interactions with other medications or natural substances.